Lataa...
Recombinant interferon in advanced breast cancer.
Fifteen patients with locally advanced refractory breast cancer have been treated with recombinant leucocyte interferon ( rIFN -alpha A) for up to 12 weeks. Toxicity was considerable with the initial dosage schedule employed but became acceptable after reducing the starting dose by 50%. Minor side e...
Tallennettuna:
| Päätekijät: | , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Nature Publishing Group
1984
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1976731/ https://ncbi.nlm.nih.gov/pubmed/6722009 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|